Skip to main content

Caris, Feist-Weiller Cancer Center Partner to Offer Tumor Profiling Services

NEW YORK (GenomeWeb) – The LSU Health Shreveport Feist-Weiller Cancer Center today announced a partnership with Caris Life Sciences to offer tumor profiling services.

As a result, patients at University Health Shreveport, a clinical partner of the LSU Health Shreveport School of Medicine, will have access to the technology, which is being provided via the Caris Molecular Intelligence service.

Caris Molecular Intelligence correlates molecular data from a tumor with biomarker and/or drug associations from clinical and scientific literature and combines traditional pathology analysis methods with DNA sequencing technologies to generate information for use in making therapeutic decisions for patients.

The partners noted that molecular profiling has become especially valuable in caring for patients with difficult-to-treat cancers, as well as for those with rare and aggressive cancers.

As part of the deal, Caris is providing clinical support, patient and physician education, and system integration. The partnership also provides a forum for joint research projects to be carried out by Caris and Feist-Weiller researchers.

"As the only institution in a 250-mile radius to offer these capabilities, our partnership with Caris is critical to providing more precise, personalized care for cancer patients treated at our center each year," said Glenn Mills, director of Feist-Weiller. "This type of technology is integral to better understanding the unique molecular characteristics of a patient's disease, which enables more targeted treatment planning."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.